To evaluate the impact of NKG2A blockade on the antitumoral efficacy induced by KISIMA—VSV-GP-TAg (KVK) vaccination, C57BL/6J mice were subcutaneously implanted with TC-1 tumor cells. The gene discussed is KLRC1; the disease is neoplasm.